Culture

Patients with PsA treated with ustekinumab are twice as likely to achieve acr20 vs. placebo

Berlin, Germany, June 8 2012: A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients with active psoriatic arthritis (PsA) treated with Ustekinumab (UST) 90mg were more than twice as likely to achieve the study's primary endpoint, ACR20* at 24 weeks, than those treated with placebo (49.5% vs 22.8%). 42.4% of patients treated with UST 45mg were also more likely to achieve ACR20 at 24 weeks compared to placebo.

Early menopause predicts a milder form of rheumatoid arthritis

Berlin, Germany, June 8 2012 : A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that early menopause predicts a milder form of rheumatoid arthritis (RA). New insights on factors influencing RA are good news for sufferers of the chronic inflammatory disease that currently affects over 2 million women in Europe. 1,2

13.7 million young adults stayed on or joined their parents' health plans in 2011

June 8, 2012, New York, NY—In 2011, 13.7 million young adults ages 19 to 25 stayed on or joined their parents' health plans, including 6.6 million who would likely not have been able to do so before passage of the Affordable Care Act, according to a new Commonwealth Fund report.

Re-defining future stroke risk among pre-diabetics

Millions of pre-diabetic Americans may be at increased risk of future stroke, say researchers at the University of California, San Diego School of Medicine in a new meta-analysis of epidemiological studies, but the precise degree of that threat is confounded by differing medical definitions and factors that remain unknown or unmeasured.

Patients suffering from pre-diabetes at potential future risk of stroke

Millions of people suffering from pre-diabetes may be at a higher risk of stroke, a study published on bmj.com today suggests.

Pre-diabetes is characterised by higher than normal blood glucose levels that, if left untreated, develops into type 2 diabetes. The scale of the problem is enormous and growing, with an estimated 79 million people in the US and 7 million people in the UK affected.

Pre-existing mutations can lead to drug resistance in HIV virus

In a critical step that may lead to more effective HIV treatments, Harvard scientists have found pre-existing mutations in a small number of HIV patients. These mutations can cause the virus to develop resistance to the drugs used to slow its progression.

Pre-existing problems

In a critical step that may lead to more effective HIV treatments, Harvard scientists have found that, in a small number of HIV patients, pre-existing mutations in the virus can cause it to develop resistance to the drugs used to slow the progression of the disease.

Safe, simple eye test may help save lives by preventing stroke

SAN FRANCISCO – June 7, 2012 – A simple eye test may someday offer an effective way to identify patients who are at high risk for stroke, say researchers at the University of Zurich. They showed that a test called ocular pulse amplitude (OPA) can reliably detect carotid artery stenosis (CAS), a condition that clogs or blocks the arteries that feed the front part of the brain. It's a known risk factor for stroke. The OPA test could be performed by ophthalmologists – physicians who treat eye diseases – during routine exams.

VCU researchers identify changes in cholesterol metabolic pathways

RICHMOND, Va. (June 7, 2012) – A new study from the Virginia Commonwealth University School of Medicine has identified molecular changes responsible for abnormal cholesterol production and metabolism in the livers of patients with a common liver condition, and these changes may explain the severity of a patient's liver disease and risks to their heart health.

11 integrated health systems form largest private-sector diabetes registry in US

(PORTLAND, Ore.) —June 07, 2012—Eleven integrated health systems, with more than 16 million members, have combined de-identified data from their electronic health records to form the largest, most comprehensive private-sector diabetes registry in the nation.

According to a new study published today in the Centers for Disease Control and Prevention's Preventing Chronic Disease, the SUPREME-DM DataLink provides a unique and powerful resource to conduct population-based diabetes research and clinical trials.

Study links teamwork, communication with quality of nursing home care

Nursing homes that foster an environment in which workers feel they are valued contributors to a team of caregivers provide better care to their residents. That is the conclusion of a study out this month in the journal Health Services Research.

Report addresses challenges in implementing new diagnostic tests where they are needed most

Easy-to-use, inexpensive tests to diagnose infectious diseases are urgently needed in resource-limited countries. A new report based on an American Academy of Microbiology colloquium, "Bringing the Lab to the Patient: Developing Point-of-Care Diagnostics for Resource Limited Settings," describes the challenges inherent in bringing new medical devices and technologies to the areas of the world where they are needed most.

By adding VSL#3 probiotic to traditional therapies UC patients can improve remission rates

GAITHERSBURG, MD, June 7 – As one of the few probiotics with medical food designation for specific illnesses, VSL#3® has been the subject of a collection of more than 80 studies that have demonstrated its use in the dietary management of IBS, ulcerative colitis, and an ileal pouch. Ulcerative colitis patients, in particular, have been shown to benefit from adding VSL#3 medical food to their prescription drug regimen.

Personalizing biologic treatment to individual patients with rheuatoid arthritis is cost-effective

Berlin, Germany, June 7 2012: Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tailoring biologic treatment to individual patients with rheumatoid arthritis (RA) can reduce total costs by €2,595,557 per 272 patients over 3 years (95 percentile range -€2,983,760 to -€2,211,755), whilst increasing effectiveness by an average of 3.67 quality-adjusted life years (QALYs)*. Cost savings were mostly on drug costs.

Treatment with anti-TNFs reduces the risk of cardiovascular events in rheumatoid arthritis

Berlin, Germany, June 7 2012: Results from a retrospective analysis of contemporary data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, predict, based on estimates from a multivariate regression model, that the cumulative use of anti-tumour necrosis factor drugs (anti-TNFs) for one, two, or three years is associated with reduced risk of cardiovascular events by 24%, 42% and 56% in patients with rheumatoid arthritis (RA) respectively, compared to not using anti-TNF therapies (adjusting for background use of methotrexate or other disease modifyin